Prognostic factors of second primary contralateral breast cancer in early-stage breast cancer.

Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033). Breast Cancer Res (2016) 0.75

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57

Prognostic and predictive factors in early-stage breast cancer. Oncologist (2004) 2.84

Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev (1999) 2.74

Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys (2003) 2.28

Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr (1985) 1.81

Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76

Second primary in the contralateral breast after treatment of breast cancer. Radiother Oncol (2007) 1.75

A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Stockholm Breast Cancer Study Group. Cancer (1998) 1.54

Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol (1995) 1.32

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2013) 1.29

uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem (2008) 1.25

Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol (2012) 1.13

Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys (2005) 1.12

Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat (2000) 1.09

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer (2013) 1.06

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel. BMC Cancer (2011) 1.03

Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn (2010) 0.98

The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast (2003) 0.97

Review of risk factors for the development of contralateral breast cancer. Am J Surg (2013) 0.94

Prognostic factors for metachronous contralateral breast cancer: a comparison of the linear Cox regression model and its artificial neural network extension. Breast Cancer Res Treat (1997) 0.90

WITHDRAWN: Tamoxifen for early breast cancer. Cochrane Database Syst Rev (2008) 0.89

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer (2004) 0.82

Long-term survival and prognostic factors in patients with regional breast cancer (skin, muscle, and/or chest wall attachment). Cancer (1985) 0.80

Prognostic importance of PAI-1 in node negative breast cancer patients--results after 10 years of follow up. Pathol Res Pract (2011) 0.80

A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer. Cancer Invest (2003) 0.80

Prognostic factors after conservative surgery and radiation therapy for early stage breast cancer. Am J Clin Oncol (1998) 0.79

Prognosis in women with breast cancer and private extra insurance coverage. Ann Surg Oncol (2013) 0.79

Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question? Clin Transl Oncol (2010) 0.78

[UPA/PAI-1: a tool for breast cancer treatment individualization. Biology, clinical implications and quantification assays]. Bull Cancer (2010) 0.78

[Breast cancer screening imaging: what do we do]. J Gynecol Obstet Biol Reprod (Paris) (2009) 0.78

The relative benefits of tamoxifen in older women with T1 early-stage breast cancer treated with breast-conserving surgery and radiation therapy. Breast J (2013) 0.77